Events
Canada targets US$37bn femtech opportunity

Vancouver forum brings policy, industry and health leaders together to tap Canada’s US$37bn femtech opportunity.
The 2025 Femtech Canada Forum brought together representatives from policy, academia, industry and global health organisations to address what organisers describe as a US$37bn economic opportunity for Canada’s economy through women’s health technology.
Femtech Canada announced it will join the United Nations Population Fund’s Equity 2030 Alliance as a member and co-lead of the Technology Cluster, becoming the first organisation to assume a cluster co-lead role within the alliance.
The Vancouver event, hosted by Femtech Canada with title sponsor Sun Life and event sponsor Deloitte Canada, focused on aligning research, policy and commercialisation efforts to address gender health disparities.
“We are excited to welcome Femtech Canada as a co-lead of the Technology Cluster,” said Dr Nigina Muntean, chief of the innovation and transformation branch at UNFPA. “Their leadership will help accelerate gender-equitable technology development and strengthen collective efforts to advance women’s health and wellbeing worldwide.”
Andrea Guest, senior manager at Femtech Canada, said the organisation was “honoured” to join the alliance. “By aligning our ecosystem work with the Alliance’s global mandate, we can accelerate the design and adoption of technologies that truly serve women’s health.”
The forum featured several report launches addressing barriers to women’s health innovation in Canada. Deloitte Canada and the IWK Foundation unveiled “The Case for Advancing Women’s Health in Canada”, which calls for updates to Canada’s Women’s Health Strategy and outlines policy gaps and economic opportunities.
Zahra Jivan from Deloitte Canada and Heather Creighton from the IWK Foundation presented recommendations for driving equitable outcomes and what they described as unlocking national prosperity through women’s health investment.
PeriPharm and Duchesnay released a white paper documenting two decades of market access challenges for women’s health medications in Canada. Catherine Beauchemin and Maggie Dong of PeriPharm presented the findings, highlighting regulatory barriers and proposing strategies for reform.
A discussion between Dr Lori Brotto from the Women’s Health Research Institute and Hilary Kilgour from Audaxa Ventures examined pathways from research to commercialisation for evidence-driven entrepreneurs in femtech.
The closing panel, moderated by Laura Maxwell from Sun Life, included Dr Angela Kaida from the Canadian Institutes of Health Research, Jessica Chalk from myStoria, Mallorie Bronfman-Thomas from the UNFPA’s Equity 2030 Alliance, and Stephanie Gan from Health Emergency Readiness Canada.
Panellists discussed embedding gender equity throughout the innovation lifecycle, from research and product development to commercialisation. They emphasised the need for inclusive data practices, investment and stronger pathways for bringing women’s health solutions to market.
“This Forum helps us form the roadmap to move from talk to tangible action,” Guest said. “We’re done talking about ‘potential’ and are now focused on the collective work to make Canada’s femtech advantage a world-leading reality.”
The annual forum rotates between Canadian cities to support regional and national growth in the femtech sector. Organisers positioned women’s health innovation as what they called one of Canada’s greatest untapped opportunities for innovation, productivity and inclusive growth, requiring national coordination and strategic positioning as an economic growth driver.
Entrepreneur
Last chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September

Early bird pricing for W Group’s two flagship October summits – Women’s Health Week Europe 2026 and Women’s Sport Summit Europe 2026 – closes on 11 September.
Both events take place at Emirates Stadium, London, bringing together founders, investors, corporates, and industry leaders shaping the future of women’s health and sport.
Women’s Health Week Europe 2026
7-8 October | Emirates Stadium, London
This year’s edition will be Women’s Health Week Europe biggest one yet: with 700+ attendees, 80+ speakers, and 20+ sponsors, it will also feature two stages – a Global Stage covering market trends and policy, and a Scale Stage focused on company-level growth and commercialisation. WHW takes place across two days of content, business matchmaking, and dealmaking.
Agenda highlights include:
- Where Capital Flows: Funding Trends in Women’s Health – with Merete Clausen (EIF), Ekaterina Gianelli (Calm/Storm), Henriette Hessen (Verdane), Jemma Day (British Business Bank), Ravit Warsha Dor (Telus Global Ventures), Tim Davis (LSEG)
- Six Feet Under-funded: Surviving the Valley of Death in Women’s Health – with Patric Stenberg (Gesynta Pharma), Valentina Milanova (Daye), Amber Vodegel (28x)
- The Women’s Health Label – Gift or Curse? · Live Debate – with Juan Camilo Arjona Ferreira (organon), Marissa Fayer (DeepLook Medical), Christian Lautner (Heal Capital), Annie Theriault (CBIV), Ida Tin (Clue)
- Passport to Scale: Taking Your Women’s Health Business Global – with Vanessa Carpenter (Femtech Across Borders), Annie Theriault (CBIV), Victorine Lançon (Daya Ventures), Dr Mridula Pore (Peppy)
Early bird pricing (ends 11 September):
| Ticket type | Early bird | Standard |
| Startups, Scaleups, Investors, Non-Profits, Government | £599 + VAT | £699 + VAT |
| Corporates, Payors & Providers | £1,799 + VAT | £1,999 + VAT |
| Service Providers & Consultants | £3,299 + VAT | £3,499 + VAT |
Register for Women’s Health Week Europe | See the full agenda for WHW
Women’s Sport Summit Europe 2026
6 October | Emirates Stadium, London
The first-ever Women’s Sport Summit expands W Group’s expertise in connecting key decision-makers to the sports industry.
WSS brings together rights holders, brands, investors, athletes, and media to accelerate commercial growth across the sector.
Agenda highlights include:
- From capital to crowd: the women’s sport cycle at scale – with Omar Shaikh (Arsenal FC), Nicole McWilliams (Google), Kerstin Lutz (Mercury13), Jo Currie (BBC Sport)
- Women’s sport through the investor lens: what gets funded – and why – Hugo Sever (APEX Capital)
- Rethinking ROI: what are we measuring that doesn’t actually matter? – Fi Watherston (Metro Bank), Silvia Keiser (Billie Jean King Cup), Gabriel Akin-Odujobi (Crux Football), Tammy Parlour (WST)
- Beyond the 90 minutes: matchday as a commercial product, not just a fixture – Maggie Murphy (Aston Villa Women FC), Sam Feasey (Diageo/Guinness), Molly Miller (OneFootball), Megan Feringa (The Athletic/The New York Times)
Early bird pricing (ends 11 September):
| Ticket type | Early bird | Standard |
| General Pass | £299 + VAT | £399 + VAT |
| Service Providers & Consultants | £1,799 + VAT | £1,999 + VAT |
Register for Women’s Sport Summit Europe | See the full agenda for WSS
Attending both events?
For group tickets or to attend both summits this October, contact Callum, W Group’s Client Success Lead, at [email protected].
Fertility
One week left to apply: W Accelerate with Merck KGaA and M Ventures

Applications close 2 September at 12pm BST for W Accelerate with Merck KGaA and M Ventures, a fast-track programme offering startups, scaleups and spinouts in reproductive and maternal health direct access to decision-makers at one of the world’s leading reproductive health companies.
With a single application, innovators connect with Merck KGaA’s partnership team and investment professionals from M Ventures, Merck’s corporate venture arm.
Selected companies will be notified on 11 September and invited to pitch at W Accelerate in London, at One Hundred Shoreditch, on 5 October.
During the event, they will receive a private 30-minute session with Merck and M Ventures leadership, small-group guidance from regulation and investment specialists, an “Ask Merck Anything” roundtable, and access to a VIP networking reception.
Applications are open to companies working on breakthrough solutions across reproductive and maternal health, including fertility, endometriosis, adenomyosis, ovarian health, preeclampsia and pregnancy comorbidities.
Applicants can choose one of three lanes, depending on whether they’re seeking strategic collaboration, investment, or both: Partnership Lane, Investment Lane, or Dual Lane. Direct-to-consumer and over-the-counter products are outside the programme’s scope.
Thang Vo-Ta, CEO & co-founder of Calla Lily Clinical Care and participant of a previous edition of W Accelerate with Merck Healthcare and M Ventures, said: “The opportunity to pitch directly to senior leadership at Merck and M Ventures sparked conversations that became the foundation of relationships leading to our eventual strategic collaboration with Merck. I’ve yet to see another event run with this level of excellence.”
For more information, visit W Group’s website: wplatform.co
Applications close 2nd September 2026, 12pm BST
W Accelerate event: 5th October 2026 at One Hundred Shoreditch, London (travel and accommodation not provided)
Apply here
Entrepreneur
WHIS 2026 adds 18 new speakers to October summit agenda

The Women’s Health Innovation Summit (WHIS), the event uniting the global women’s health ecosystem, has just announced 18 new speakers joining the agenda for its 2026 summit, taking place October 13–15 at Encore Boston Harbor.
The latest additions bring further depth across pharma, clinical research, health systems, venture, and policy, reinforcing WHIS’s role as the only platform where the full women’s health ecosystem convenes under one roof.
Newly confirmed speakers include:
- Kelle Moley, MD – VP, Women’s Health Early Phase Clinical Development, Cardiometabolic Research, Eli Lilly & Company
- Justine Levin-Allerhand – Executive Partner, Chief Corporate Development Officer & COO, Flagship Labs, Flagship Pioneering
- Sebnem Yildirimoglu, MD, PMP – Executive Director, Women’s Health Strategy, Premier Research
- Terri Stewart – Head of Global Healthcare & Government Affairs, EMD Serono
- Dr. Morag Grassie – Executive Director, Blavatnik Fund for Innovation, Yale
- Sandra Butler – Director, Design Impact, Mass General Brigham
- Zhenya Lindgardt – Chief Executive Officer, Sera Prognostics
- Sadie Morahan – Head of US Revenue, Withings Health Solutions
- Angela Drew, PhD – Vice President, Regulatory Strategy, Premier Research
- Dr. Stephanie Lahr – CMIO, Aqurio
- Michelle Andrews – Contributing Writer, KFF Health News
- Charlotte Williams – CEO, My Bump Hub
- Clint Dart, MS – Director, NIH Women’s Health Data Coordinating Center, Premier Research
- Cass Sanford – US Venture Advisor, FemTech Lab
- Megan Mukuria – Founder & CEO, ZanaAfrica
- Tiffany Inglis, MD, FACOG – Chief Medical Officer, Sera Prognostics
- Angelean Hendrix, PhD – Vice President, Pharmacometrics and MIDD, Premier Research
- Amanda Ducach – CEO & Co-founder, EmaEQ
“WHIS is where the women’s health industry comes together to take action,” said Poppy Howard-Wall, Event Director at WHIS.
“This latest wave of speakers reflects exactly the kind of cross-sector expertise our attendees expect – from global pharma and clinical research leadership to venture, health systems, and grassroots innovation.
“It’s this breadth that makes WHIS the room where things actually move forward.”
Bringing the Full Ecosystem Together
These additions join a growing 2026 agenda spanning four content tracks that reflect the full lifecycle of healthcare innovation, from early-stage research and development through to patient delivery, system transformation, and commercial scale.
Attendees can expect over 1,000 senior decision-makers, 120+ expert speakers, four dedicated stages, and more than 10 hours of curated 1:1 meetings.
Full speaker and agenda details are available at whisusa.com/speakers-2026.
About WHIS
The Women’s Health Innovation Summit is the only platform uniting the full women’s health ecosystem – providers, payers, employers, pharma leaders, investors, and innovators -to increase deal flow, expand reimbursement, improve access, and deliver better outcomes for women at every stage of life.
Entrepreneur1 week agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy2 weeks agoUK study aims to transform maternity care for high-risk pregnancies
Fertility2 days agoParacetamol use may impact future fertility, studies suggest
Entrepreneur5 days agoLast chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Hormonal health1 week agoMenopause hormone treatment may ease brain fog, study suggests
Menopause4 days agoCancer drug could tackle osteoporosis menopause weight gain
News2 weeks agoSpanish agency criticised for menopause guidelines based on male studies










